The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://luluvwsk237737.like-blogs.com/38584590/retatrutide-vs-tirzepatide-a-comparative-analysis